mRNA vaccines against COVID‐19: a showcase for the importance of microbial biotechnology

• Published in: Microbial biotechnology Vol. 15; no. 1; pp. 135 - 148
• Main Author: Brüssow, Harald
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.01.2022; John Wiley and Sons Inc; Wiley
• Subjects: Aged; Antibodies; Biotechnology; Biotechnology industry; Chills; Collaboration; Coronaviruses; COVID-19; COVID-19 Vaccines; Drug dosages; Facial nerve; Fever; Glycoproteins; Headache; Heart diseases; Humans; Injection; Lipid composition; Lipids; Male; Medical research; Microorganisms; mRNA; mRNA Vaccines; Muscles; Muscular fatigue; Myocarditis; Nanoparticles; Neutralization; Nobel prizes; Observational studies; Pain; Pandemics; Paralysis; Physiology; Population studies; Populations; Protein composition; Protein expression; Proteins; RNA polymerase; SARS-CoV-2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Special Issue; Spike Glycoprotein, Coronavirus; Spike protein; Uridine; Vaccine Efficacy; Vaccines; Vaccines, Synthetic; Viral diseases

Summary Pfizer‐BioNTech and Moderna developed in record time mRNA vaccines against COVID‐19 of high efficacy. The modest protection achieved with a similarly designed mRNA from CureVac underlines the importance of biotechnological details in formulation such as replacement of uridine by pseudouridin...